Diagnostic techniques and prognostic indicators

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Chavan SS et al. Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12. CD117 (KIT) Is A Useful Marker in The Diagnosis of Plasmablastic Plasma Cell Myeloma. Marks E et al. Histopathology. 2017 Feb 22. doi: 10.1111/his.13196. [Epub ahead of print]. In vivo confocal microscopy of multiple myeloma associated…

Details

Related conditions

Periorbital papules as a presenting sign in multiple myeloma with AL amyloidosis. Vilcassim FS et al. BMJ Case Rep. 2017 Feb 20;2017. pii: bcr2016219010. doi: 10.1136/bcr-2016-219010. Amyloidosis: A cancer-derived paraproteinemia and kidney involvement. Małyszko J et al. Adv Med Sci. 2017 Jan 30;62(1):31-38. doi: 10.1016/j.advms.2016.06.004. [Epub ahead of print]. Pure Red Cell Aplasia Associated with Monoclonal Gammopathy of Undetermined Significance and Literature Review.…

Details

Emerging treatments

Conditioning regimens for autologous haematopoietic stem cell transplantation – can natural killer cell therapy help? Snowden JA et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14565. [Epub ahead of print]. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Vogl DT et al. Leuk Lymphoma. 2017 Jan 31:1-11. doi: 10.1080/10428194.2016.1263842. [Epub ahead of print].…

Details

Biology and genetics

Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Rossi A et al. Blood Cancer J. 2017 Feb 24;7(2):e537. doi: 10.1038/bcj.2017.19. Ecto-5′ -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriolopathy in dialysis patients – Data from the German Calciphylaxis Registry. Rothe H et al. PLoS One. 2017…

Details

General

Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population-based study. Howell D et al. Br J Haematol. 2017 Feb 1. doi: 10.1111/bjh.14513. [Epub ahead of print]. High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. Lisenko K et al. BMC Cancer. 2017 Feb 22;17(1):151. doi: 10.1186/s12885-017-3137-4. Association between response rates…

Details

Supportive treatments

Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. Palmaro A et al. Pharmacoepidemiol Drug Saf. 2017 Feb 15. doi: 10.1002/pds.4180. [Epub ahead of print]. Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Cho YK et al. Clin Pharmacol Ther. 2017 Feb 4. doi: 10.1002/cpt.644. [Epub…

Details

Complications of myeloma and its treatments

Renal failure in multiple myeloma: something new on the horizon. Offidani M et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14548. [Epub ahead of print]. Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients. Vázquez L et al. Rev Esp Quimioter. 2017 Feb 14. pii: vazquez14feb2017. [Epub ahead of print]. Myelosuppression-sparing treatment of central nervous…

Details

Current treatments

Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. Berdeja JG et al. Br J Haematol. 2017 Feb 7. doi: 10.1111/bjh.14536. [Epub ahead of print]. Impact of induction treatment before autologous stem cell transplantation on long term outcome in patients with newly diagnosed multiple…

Details

EMA recommends expanded daratumumab indication for myeloma

Genmab and Janssen have announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation to expand the existing market licence for daratumumab (Darzalex®) as a treatment for relapsed and/or refractory myeloma patients. Currently licensed as a monotherapy, the latest recommendation is for the use of…

Details